Quantum BioPharma

Call Directions Website

Quantum BioPharma Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM

10/11/2026

🧠 ADVANCING THE FIGHT AGAINST MULTIPLE SCLEROSIS!

A major step forward for Quantum BioPharma (NASDAQ: QNTM)!

Following FDA clearance, Quantum BioPharma is advancing its Phase 2 clinical development program for progressive Multiple Sclerosis (MS), marking an important milestone in the pursuit of innovative treatment options.

With a clinical trial agreement in place, we're moving closer to evaluating the potential of our groundbreaking research to make a meaningful difference for people living with MS.

Science. Innovation. Hope. The future of MS treatment starts with progress.

🌐 www.quantumbiopharma.com

10/09/2026

A Major Milestone for Quantum BioPharma & Lucid-MS

Quantum BioPharma (NASDAQ: QNTM) is moving Lucid-MS forward toward Phase 2, entering into a Study Start-Up Agreement with the PPD™ Clinical Research Business of Thermo Fisher Scientific.

Following FDA clearance to proceed, formal study start-up activities are now underway for the planned Phase 2 multiple sclerosis trial.

A significant step forward in our mission to develop a potentially first-in-class neuroprotective approach for MS.

The next chapter for Lucid-MS starts now.

A Major Milestone for Quantum BioPharma & Lucid-MSQuantum BioPharma (NASDAQ: QNTM) is moving Lucid-MS forward toward Pha...
10/06/2026

A Major Milestone for Quantum BioPharma & Lucid-MS

Quantum BioPharma (NASDAQ: QNTM) is moving Lucid-MS forward toward Phase 2, entering into a Study Start-Up Agreement with the PPD™ Clinical Research Business of Thermo Fisher Scientific.

Following FDA clearance to proceed, formal study start-up activities are now underway for the planned Phase 2 multiple sclerosis trial.

A significant step forward in our mission to develop a potentially first-in-class neuroprotective approach for MS.

The next chapter for Lucid-MS starts now.

Big News for unbuzzd™Quantum BioPharma is pleased to announce the appointment of visionary entrepreneur Michael “Zappy” ...
09/24/2026

Big News for unbuzzd™

Quantum BioPharma is pleased to announce the appointment of visionary entrepreneur Michael “Zappy” Zapolin as CEO of Unbuzzd Wellness Inc.

From Wall Street to pioneering internet ventures and next-generation wellness, Zappy brings decades of entrepreneurial experience, brand-building expertise and an extensive network to unbuzzd. His mandate: help finance and list Unbuzzd on a stock exchange and lead the ex*****on of a nationwide U.S. commercial marketing and product rollout.

Science-backed. Clinically validated. Built for a massive consumer opportunity.

unbuzzd™ is backed by a peer-reviewed clinical study supporting its ability to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms.

As Zappy puts it: “I believe unbuzzd has the potential to help millions of lives, and I’m honored to help bring it forward.”

The next chapter of unbuzzd™ starts now.

🌐 Discover unbuzzd: unbuzzd.com
📈 Quantum BioPharma Ltd. — NASDAQ: QNTM | FRA: 0K91

Advancing Science. Saving Lives.



🚀 NEW ANALYST COVERAGE FOR QUANTUM BIOPHARMAQuantum BioPharma Ltd. (NASDAQ: QNTM) is pleased to announce that Rodman & R...
09/17/2026

🚀 NEW ANALYST COVERAGE FOR QUANTUM BIOPHARMA

Quantum BioPharma Ltd. (NASDAQ: QNTM) is pleased to announce that Rodman & Renshaw has initiated analyst coverage of the Company with a BUY rating and a US$8 price target.

This new coverage comes as Quantum BioPharma continues advancing its innovative therapeutic pipeline and pursuing its mission to develop transformative treatments in areas of significant unmet medical need.

🧬 BUY Rating
🎯 US$8 Price Target
📈 Independent Analyst Coverage
🔬 Advancing a Next-Generation Therapeutic Pipeline

The future of medicine starts with bold science.

Quantum BioPharma — Advancing Science. Saving Lives.

Quantum BioPharma is heading to the ArcStone-Kingswood Growth Summit 2026 in Toronto! 🇨🇦Quantum BioPharma Ltd. (NASDAQ: ...
09/15/2026

Quantum BioPharma is heading to the ArcStone-Kingswood Growth Summit 2026 in Toronto! 🇨🇦

Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) is pleased to participate in the 3rd Annual ArcStone-Kingswood Growth Summit on September 16, 2026, at the Sheraton Centre Toronto Hotel.

Anthony Durkacz, Co-founder and Executive Co-chairman, will present Quantum BioPharma’s recent milestones and future growth strategy to investors, family offices and capital markets professionals.

The presentation comes at an important time for Quantum BioPharma following the FDA’s approval of the Investigational New Drug (IND) application for Lucid-MS, allowing the Company to advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical trials in patients with progressive MS.

📍 Toronto, Ontario
📅 September 16, 2026
🏨 Sheraton Centre Toronto Hotel

Interested investors can register for a FREE PASS:

https://www.meetmax.com/sched/event_144037/investor_reg_new.html?attendee_role_id=ARCSTONE_ATTENDEE

Quantum BioPharma (NASDAQ: QNTM). The company is advancing Lucid-21-302, a novel oral therapeutic candidate targeting pr...
08/31/2026

Quantum BioPharma (NASDAQ: QNTM). The company is advancing Lucid-21-302, a novel oral therapeutic candidate targeting protein arginine deiminase, or PAD, biology in multiple sclerosis. The program offers a differentiated approach centered on neuroprotection and myelin preservation, with several important development milestones ahead.

Please reach out directly or at [email protected] to request the full initiation report. More to come.

08/10/2026

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis

Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination

Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide

https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html

07/24/2026

Most MS therapies modulate immunity. Quantum BioPharma’s investigational Lucid-MS is designed to address citrullination and myelin integrity through a differentiated, non-immunosuppressive approach.

Learn more: https://www.quantumbiopharma.com/lucid-ms

$QNTM

Address

1 Adelaide Street East Suite 801
Toronto, ON
M5C2V9

Telephone

+14168548884

Website

Alerts

Be the first to know and let us send you an email when Quantum BioPharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category